Chemists know the relationships: Laetrile develops a “bitter” effect, which can be directed against cancer cells. When laetrile, vitamin B17, is consumed, the liver activates a special enzyme (beta-glycosidase) to transform the vitamin B17, laetril, in a molecule of benzaldehyde (an analgesic) and a hydrogen cyanide molecule. Cyanide (prussic acid) is highly toxic and dangerous depending on the dosage. But not for all cell types: tumor tissue has far more enzymes, type beta-glycosidase, than normal cells. Therefore, cancer cells divide more frequently laetrile, vitamin B17, and generate more anticarcinogenic cyanides. The cancer cell is about to poison itself.
B17 and IPT. Insulin multiplies the effect of the vitamin’s.
Healthy cells remain unaffected by anticarcinogenic cyanides. They neutralize them thanks to the enzyme rhodanese. Only healthy cells contain the enzyme rhodanese.
But cancer cells are not immune: they react to laetrile, vitamin B17, as they have no protective armor against laetrile, vitamin B17. Supplying laetril, vitamin B17, via an insulin potentiation therapy (IPT) has the advantage supplying it (laetril, vitamin B17) in a highly concentrated form directly into cancer cells.
Insulin and vitamin B17 (laetril) go hand in hand: Thanks to an insulin potentiation therapy (IPT) the dosage can be reduced significantly. Laetril, B17, is introduced into cancer cells riding insulin somehow “piggyback”. This way laetril, vitamin B17, can be reduced to one fifth of the amount normally used and directed to cancer cells.
Using an insulin potentiation therapy (IPT) an infusion therapy with laetril, vitamin B17, can become more effective as laetril, vitamin B17, is widely and selectively distributed within our body.
The goal of an insulin potentiation therapy in combination with vitamin B17, laetril, is that an insulin potentiation therapy attacks only where it is needed.
An insulin potentiation therapy sees itself as a natural laetril, vitamin B17, chemotherapy and feeds selectively and highly concentrated only cancer cells with anticarcinogenic cyanides.